Maria Gogou

Dr. Maria Gogou


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2019 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
MGMaria Gogou
Maria Gogou
KHKaterina Haidopoulou
Katerina Haidopoulou
EPEvangelos Pavlou
Evangelos Pavlou


30 May 2018 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
MGMaria Gogou
Maria Gogou
GKGeorge Kolios
George Kolios

1 July 2016 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
MSMartha Spilioti
Martha Spilioti
EPEvangelos Pavlou
Evangelos Pavlou
MGMaria Gogou
Maria Gogou
IKIrene Katsanika
Irene Katsanika
EPEfimia Papadopoulou-Alataki
Efimia Papadopoulou-Alataki
AEAthanasios Evangeliou
Athanasios Evangeliou

9 February 2021 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
MGMaria Gogou
Maria Gogou
JCJ Helen Cross
J Helen Cross
Fenfluramine hydrochloride has classically been described as acting pharmacologically through a serotonergic mechanism. Therefore, it was initially used as an anorectic drug, given that impaired serotonin homeostasis may be associated with increased food intake. Although positive results were documented, cardiovascular concerns resulted in its temporary withdrawal. Nevertheless, a novel role in patients with epilepsy was later suggested by isolated clinical observations. The wide application of genetic testing allowed the classification (predominantly as Dravet syndrome) of patients in whom benefit was seen, while with the development of zebrafish models, its antiepileptic properties were confirmed at a molecular level. Data from randomized clinical trials have shown a beneficial effect of fenfluramine, as an adjunct therapy, on seizure control for children with Dravet syndrome, though there is still uncertainty about the impact on neurodevelopment in these patients. No signs of heart valve disease have been documented to date. Long‐term and appropriately designed clinical studies will verify whether fenfluramine is a therapeutic agent of high importance, living up to the promise shown so far. What this paper adds: Fenfluramine is a very promising repurposed therapy specifically for seizures in Dravet syndrome. The long‐term effect of fenfluramine on neurodevelopmental prognosis requires further investigation.

18 November 2014 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
MGMaria Gogou
Maria Gogou
KHKaterina Haidopoulou
Katerina Haidopoulou
MEMaria Eboriadou
Maria Eboriadou
EPEvaggelos Pavlou
Evaggelos Pavlou